Maven Bio

Executive Summary

Maven Bio is a preclinical-stage biotechnology company leveraging a proprietary AI/ML platform to design novel protein therapeutics for oncology and immunology. Founded in 2020 and headquartered in Cambridge, MA, the company integrates deep learning models of protein structure with generative chemistry and high-throughput functional screening to rapidly identify first-in-class biologics, including antibodies and engineered proteins. With $150 million raised to date, Maven Bio addresses significant unmet medical needs through its computational approach, which aims to reduce the time and cost of drug discovery while improving candidate quality. The company is advancing its lead pipeline toward regulatory milestones, with a focus on validating its platform through preclinical studies. Key upcoming catalysts include the submission of an IND application for its lead oncology candidate, expected in the latter half of 2026, and potential expansion of its pipeline through strategic partnerships with larger pharmaceutical companies. Maven Bio's strong funding base and innovative platform position it as a compelling player in the AI-driven drug discovery space, though execution risks remain given its early stage.

Upcoming Catalysts (preview)

• Q3 2026IND submission for lead oncology candidate75% success
• Q4 2026Strategic partnership with large pharma for platform access60% success
• Q2 2026Publication of key preclinical validation data80% success